title: Income and outcome in myelodysplastic syndrome: the prognostic impact of SES in a single-payer system.
abstract: We examined the prognostic impact of SES, estimated by census median household income, in 312 adult MDS patients. Age, progression to AML, use of recombinant erythropoietin, WHO diagnosis and IPSS risk category were independent predictors of survival but there was no association between SES and survival. Unexpectedly, progression to AML was more prevalent in the highest income quartile (HR 3.96 for highest vs. lowest; p=0.0032). The previously demonstrated association of low SES with poor outcome MDS in the United States may have been driven primarily by reduced access to care rather than other SES-linked factors such as co-morbidity.
authors.affiliation: MDS Research Program, Medical Oncology/Hematology, Sunnybrook Odette Cancer Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada.
authors.forename: James T
authors.initials: JT
authors.lastname: England
authors.forename: Liying
authors.initials: L
authors.lastname: Zhang
authors.forename: Rena
authors.initials: R
authors.lastname: Buckstein
authors.forename: Martha
authors.initials: M
authors.lastname: Lenis
authors.forename: Claudia
authors.initials: C
authors.lastname: Li
authors.forename: Craig
authors.initials: C
authors.lastname: Earle
authors.forename: Richard A
authors.initials: RA
authors.lastname: Wells
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000191:economics* / Q000401:mortality*; D011379:Prognosis; D018855:Single-Payer System / Q000191:economics*; D012959:Socioeconomic Factors; D015996:Survival Rate; D014481:United States; D055815:Young Adult
keywords: Median household income; Myelodysplastic syndromes (MDS); Prognosis; Socioeconomic status